Pfizer’s Strategic Stakes in the Weight-Loss War
Pfizer’s pursuit of Metsera is rooted in the biotech’s promising GLP-1 diabetes and obesity treatment pipeline—a direct threat to Novo Nordisk’s market dominance with Ozempic and Wegovy.
“Acquiring Metsera marks a unique and irreplaceable opportunity for Pfizer,” the company said, emphasizing that any delay would harm its competitive position in the fast-growing weight management drug space.
Responses and Legal Teams
Pfizer said in a statement that it is “taking this action to enforce and preserve its rights”, adding that the conduct of Metsera’s board and Novo Nordisk “clearly violates contractual and legal obligations.”
Metsera countered Friday, saying it “disagrees with the allegations in Pfizer’s complaint and will address them in court.” Novo Nordisk did not immediately comment.
Pfizer is represented by Jonathan M. Moses, Ryan A. McLeod, Carrie M. Reilly, and Adam L. Goodman of Wachtell Lipton Rosen & Katz, alongside Kevin R. Shannon, Berton W. Ashman Jr., Mathew A. Golden, and Callan R. Jackson of Potter Anderson & Corroon LLP.
Counsel information for Metsera and Novo Nordisk was not immediately available.
